Skip to navigation Skip to content

Chronic rhinosinusitis with nasal polyps (CRSwNP) in Pharmaceutical Benefits Scheme (PBS) 012-23031433

Expand/Collapse all sectionsExpand all


This document outlines details of PBS-subsidised mepolizumab for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

CRSwNP and listing dates

CRSwNP is a chronic inflammatory disease of the nasal mucosa and paranasal sinuses with nasal polyps.

Listing date: mepolizumab - 1 April 2023.

See Written Authority Required Drugs for more details.

Enquiries

Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated.

The Resources page contains:

  • application forms
  • contact details
  • restriction and item codes
  • the PBS schedule
  • Services Australia website link

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)

Process telephone Authority Approval application

Processing and National Demand Allocation (PaNDA)

Processing Complex Authority Required Listings

Processing Written Authority requests

Written Authority Required Drugs